# Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

> **NCT04738487** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1264 (actual)

## Conditions studied

- Lung Neoplasms
- Non-Small-Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab/Vibostolimab
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04738487
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-07
- **Primary completion:** 2024-09-05
- **Final completion:** 2026-01-27
- **Target enrollment:** 1264 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04738487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04738487, "Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04738487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*